Shigellosis : challenges & management issues.

Simple item page
dc.contributor.authorSur, Dipikaen_US
dc.contributor.authorRamamurthy, Ten_US
dc.contributor.authorDeen, Jacquelineen_US
dc.contributor.authorBhattacharya, S Ken_US
dc.date.accessioned2004-11-14en_US
dc.date.accessioned2009-05-27T07:42:59Z
dc.date.available2004-11-14en_US
dc.date.available2009-05-27T07:42:59Z
dc.date.issued2004-11-14en_US
dc.description62 references.en_US
dc.description.abstractInfectious diseases kill about 11 million children each year while acute diarrhoeal diseases account for 3.1 million deaths in children under 5 yr of age, of which 6,00,000 deaths annually are contributed by shigellosis alone. Shigellosis, also known as acute bacillary dysentery, is characterized by the passage of loose stools mixed with blood and mucus and accompanied by fever, abdominal cramps and tenesmus. It may be associated with a number of complications of which haemolytic uraemic syndrome is the most serious. Shigellosis is caused by Shigella spp. which can be subdivided into four serogroups namely S.sonnei, S.boydii, S.flexneri and S.dysenteriae. Organisms as low as 10-100 in number can cause the disease. Shigellosis can occur in sporadic, epidemic and pandemic forms. Epidemics have been reported from Central American countries, Bangladesh, Sri Lanka, Maldives, Nepal, Bhutan, Myanmar and from the Indian subcontinent, Vellore, eastern India and Andaman and Nicobar islands. Plasmid profile of shigellae in Kolkata has shown a correlation between presence of smaller plasmids and shigellae serotypes- indicating epidemiological changes of the species. Diagnosis of shigellosis is essentially clinical. Laboratory diagnosis includes stool culture and polymerase chain reaction (PCR). Treatment includes use of an effective antibiotic, rehydration therapy (if there is dehydration) and appropriate feeding during and after an episode of shigellosis. Hand-washing is the single most important strategy for prevention of transmission of shigellosis from person to person. A safe and effective vaccine should be developed against the more important circulating strains i.e., S. dysenteriae type 1 and S. flexneri 2a.en_US
dc.description.affiliationNational Institute of Cholera & Enteric Diseases, Kolkata, India. bsujit@vsnl.neten_US
dc.identifier.citationSur D, Ramamurthy T, Deen J, Bhattacharya SK. Shigellosis : challenges & management issues. Indian Journal of Medical Research. 2004 Nov; 120(5): 454-62en_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/21791
dc.language.isoengen_US
dc.source.urihttps://icmr.nic.in/ijmr/ijmr.htmen_US
dc.subject.meshDiagnosis, Differentialen_US
dc.subject.meshDrug Resistance --physiologyen_US
dc.subject.meshDysentery, Bacillary --drug therapyen_US
dc.subject.meshFeces --microbiologyen_US
dc.subject.meshHumansen_US
dc.subject.meshShigella --geneticsen_US
dc.subject.meshShigella Vaccinesen_US
dc.titleShigellosis : challenges & management issues.en_US
dc.typeJournal Articleen_US
dc.typeReviewen_US
Files
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.79 KB
Format:
Plain Text
Description:
Download
Collections
Indian Journal of Medical Research